Anteris Technologies Ltd (AMEUF)
Anteris Technologies Ltd operates in the Medical - Devices industry of the Healthcare sector, headquartered in Toowong, QLD, AU. The stock last traded at $5.70, down 35.81% on the session, giving a market capitalisation of $120.5M. On trailing twelve-month figures it carries a trailing P/E of -3.77, a net margin of -5115.6%. Its beta of 0.75 implies it has historically moved less than the broad market.
Anteris Technologies Ltd. is a medical device company focused on structural heart solutions. The firm manufactures and commercializes ADAPT, an advanced regenerative tissue product. Additionally, Anteris is actively developing DurAVRTM, a novel 3D, single-piece aortic valve designed to treat aortic stenosis. The company also conducts research and development in the broader field of regenerative medicines. Established in 1999, it changed its name from Admedus Limited to Anteris Technologies Ltd. in May 2020 and is headquartered in Toowong, Australia.
Anteris Technologies Ltd is most often compared with the following Healthcare names: